LIC
IART icon

Laurus Investment Counsel’s Integra LifeSciences IART Stock Holding History

Laurus Investment Counsel’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-42,593
Closed -$3.65M – 43
2021
Q4 		$3.65M Hold
42,593
– – 0.94% 20
2021
Q3 		$3.7M Buy
42,593
+6,660
+19% +$471K 1.05% 19
2021
Q2 		$3.04M Buy
+35,933
New +$2.54M 0.93% 18

Other funds holding IART

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Laurus Investment Counsel's IART Position: Q1 2022 in Review

Laurus Investment Counsel sold out of Integra LifeSciences (IART) in Q1 2022, closing a stake of 42,593 shares — an estimated $3.65M sold.

Laurus Investment Counsel first reported a position in IART in Q2 2021 and held it in 3 quarters. The position peaked at $3.7M in Q3 2021. 278 funds tracked by Wall St. Rank hold IART as of Q1 2022.

  • Laurus Investment Counsel reported no remaining Integra LifeSciences position as of Q1 2022 after selling out during the quarter.
  • Laurus Investment Counsel sold 42,593 Integra LifeSciences shares in Q1 2022, an estimated $3.65M.
  • Laurus Investment Counsel first reported a position in Integra LifeSciences in Q2 2021 and held it in 3 quarters.
  • Laurus Investment Counsel's Integra LifeSciences position peaked at $3.7M in Q3 2021.
  • 278 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2022.

Based on Laurus Investment Counsel's 13F filing for Q1 2022, filed 20 Apr 2022.